R&D Harnessing the cell's own degradation machinery, with Benedi... Benedict Cross, Chief Technology Officer at PhoreMost, discusses targeted protein degradation.
R&D On CB1s as an alternative to GLP-1s, with Punit Dhillon In a new pharmaphorum podcast, Punit Dhillon, CEO of Skye Bioscience, discusses CB1 inhibitor antibodies in the obesity space.
R&D Towards a democratic era of medicine, with Simon Kohl In a new episode, Simon Kohl discusses Latent Labs’ emergence from stealth, as well as protein design and drug discovery acceleration in more detail.
R&D CDMOs: Their crucial role and how to select one, with Sigma ... Sigma Mostafa, CSO at KBI BioPharma, discusses the role of CDMOs and the important factors companies should consider when selecting one.
R&D On US drug shortages and compounding pharmacies, with Shawn ... Shawn Hodges, CEO of Revelation Pharma, discusses the true state of drug shortages in the US at the moment and the role of compounding pharmacies.
R&D On inflammation, heart health, and GLP-1 possibilities, with... Sandeep Kulkarni, CEO of Tourmaline Bio, discusses inflammation, & the impact of AI and GLP-1s on cardiology clinical trials and drug development.
Patients Using patient data to fill in GLP-1 blind spots, with Phil J... At Reuters Pharma USA, Evidation Health's Phil Johnson talks about what pharma needs to know about their GLP-1 patients and how better data can help.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
